FreeStyle Libre

mine too !

 

No true.

 

Sacre bleu! It's Libre-Boy!!!!

Where have you been??!? Nice string of posts today.

 

Yawn .... Eh? Oh, that?... (fart, stretch) ... don't you have to apply for for FDA first? Wake me up in a year or two....

 

DOA in the USA: Plans won't cover, except of some Type I's. EU test has been OK, but can't launch: unsubsidized, it will be a "cash" product (not covered by socialized healthcare), so very small market potential. ABT now trying 3rd world places, like the Australia, but they're socialists too, so if it does ever launch, it will be a limited cash market.

 

Sad but true. My DM and I talked about these post on a call today. I asked if there was anything to these posts. I know better, but was I guess hoping maybe .... He said these are just a new round of posts from that same poor Irishman, nicknamed "Libra Boy", who has been positing these sad, pathetic threads trying to talk up Libra. Like this will save his job or something. Libra was supposed to save ADC, or at least attract a buyer. Too little too late. And too bad.

 

There is a remote, very remote, possibility that a "pro" version, designed to provide info to the doc, and not patient friendly, might squeak into the very end of 2016. This is not the same unit being tested in Europe, and sales would be too small to make much impact at all to our numbers, even if was around for most of 2017.

 

From what I recall reading (consumer blogs, news articles, etc), the test market in the UK revealed a variety of problems. While I think many of those were QC and shoddy workmanship, I think there were things that had to be tackled on efficacy. On one hand, that's to be expected, since that is one purpose of a test market. But you have to consider WHY they pick the EU to test this: it's much, much, much easier to get past their version of the FDA. Playing with FDA is the Big Leagues. Abbott applied last summer or fall to the FDA. It takes years to get through the FDA... under normal circumstances.

In Libra's case, this is a whole new class of products. For example, on BGM, the FDA established what the scale of measurement is, mandates that all BGM products deliver results based on that scale, and regulates that all meters must perform (accuracy) within tight parameters to that scale. We know CGM results are not aligned with that scale, and by definition regarding performance this a whole new world. Now that others have beat us to the market, the FDA is going to slow down approvals of additional products until it can standardize things, like they did with BGM.

 

Libre is now in Greece. Many other companies are doing a me too on this type of product. I figure Libre will move into other countries and do ok.

But the FDA hurdle may be too great.

 

Libre Boy is English. They all work in Whitney, UK.

 

Great. Another 3rd world $hit hole. Nice going Abbott...

 

Libre doing well. Lots of new users and more coming. Is Abbott making any money off of this? It's generating revenue but how much is the profit?

 

Yes, Libre is on FIRE! At least 16 new Leprechauns bought one in August alone! Once we eliminate the subsidy, it will be very close to being profitable. Er, that's as long as the elves are willing to pay the full cost.... Of course they will; the UK economy is on fire as well, with all the good jobs and high salaries anyone could ask for, right? I mean, people have some much extra cash laying around they are just pissing money away, so why not on Libre too!

 

Gee, the guy was just asking a simple question....

 

find work troll and pull that hair out in the mean time 2 FUNNI

 

Abbott have been pretty smart in maintaining the illusion of "growth" in Libre sales by a staged release country by country.

But unless Abbott commit to a full scale United States launch Libre will remain on the fringes of the market, no more than an annoyance to Dexcom.

 

Total revenue from Libre, based on 1.5 sensors a month and 125K users, is $131M/yr. Dexcom reported $400M is sales for the year. Not a fringe, but about 1/3 of Dexcom.

 

I heard this too !

 

That guess would be for total UK sales. Less the subsidy, what is net sales? $90M? Maybe $100M? So at best 1/4 Dexcom. Dexcom is not subsidized. Dexcom is just starting out ... in thee key USA market. Meaning as the market leader, they can double or triple their $400M before ADC even gets on ground here.

 

This is why Abbott has not, and will not, launch Libre in the US for general sale. The competition is already far too strong.

Abbott are playing a smoke and mirrors game with Libre. It is losing money on it because most of the production ends up in the scrap bin. This problem isn't well known generally but potential ADC buyers are well aware of it - which is why MW is struggling to sell the business.